Interaction potential of the endothelin: a receptor antagonist atrasentan with drug transporters and drug-metabolising enzymes assessed in vitro
Atrasentan is a highly potent and selective endothelin receptor A (ETA) antagonist under development for the treatment of prostate cancer. Only little data exist on its interaction with drug-metabolising enzymes and drug transporters possibly influencing its safety and effectiveness. Our study evalu...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) Editorial |
| Language: | English |
| Published: |
31 July 2011
|
| In: |
Cancer chemotherapy and pharmacology
Year: 2011, Volume: 68, Issue: 4, Pages: 1093-1098 |
| ISSN: | 1432-0843 |
| DOI: | 10.1007/s00280-011-1715-8 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1007/s00280-011-1715-8
|
| Author Notes: | Johanna Weiss, Walter Emil Haefeli |
| Summary: | Atrasentan is a highly potent and selective endothelin receptor A (ETA) antagonist under development for the treatment of prostate cancer. Only little data exist on its interaction with drug-metabolising enzymes and drug transporters possibly influencing its safety and effectiveness. Our study evaluated whether atrasentan can induce the expression of relevant human drug transporters and cytochrome P450 isozymes (CYPs), whether it retains its efficiency in multidrug resistant cell lines, and whether it inhibits P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP). |
|---|---|
| Item Description: | Gesehen am 18.11.2022 |
| Physical Description: | Online Resource |
| ISSN: | 1432-0843 |
| DOI: | 10.1007/s00280-011-1715-8 |